This website is intended for healthcare professionals only

NICE Technology Appraisal 358: Tolvaptan for treating autosomal dominant polycystic kidney disease

Disclaimer: Information intended for healthcare professionals only. The production and printing of this Guidelines Technology Appraisal Card has been funded by Otsuka Pharmaceutical (UK) Ltd. Otsuka Pharmaceutical (UK) Ltd has reviewed this card for technical accuracy and regulatory compliance.

Visit our NEW site!

Guidelines for Nurses provides current, credible summaries and feature articles developed especially for nurses.